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Abstract
BACKGROUND—Epidemiological studies show that high circulating cystatin C is associated 
with risk of cardiovascular disease (CVD), independent of creatinine-based renal function 
measurements. It is unclear whether this relationship is causal, arises from residual confounding, 
and/or is a consequence of reverse causation.
OBJECTIVES—The aim of this study was to use Mendelian randomization to investigate 
whether cystatin C is causally related to CVD in the general population.
METHODS—We incorporated participant data from 16 prospective cohorts (n = 76,481) with 
37,126 measures of cystatin C and added genetic data from 43 studies (n = 252,216) with 63,292 
CVD events. We used the common variant rs911119 in CST3 as an instrumental variable to 
investigate the causal role of cystatin C in CVD, including coronary heart disease, ischemic stroke, 
and heart failure.
RESULTS—Cystatin C concentrations were associated with CVD risk after adjusting for age, 
sex, and traditional risk factors (relative risk: 1.82 per doubling of cystatin C; 95% confidence 
interval [CI]: 1.56 to 2.13; p = 2.12 × 10−14). The minor allele of rs911119 was associated with 
decreased serum cystatin C (6.13% per allele; 95% CI: 5.75 to 6.50; p = 5.95 × 10−211), explaining 
2.8% of the observed variation in cystatin C. Mendelian randomization analysis did not provide 
evidence for a causal role of cystatin C, with a causal relative risk for CVD of 1.00 per doubling 
cystatin C (95% CI: 0.82 to 1.22; p = 0.994), which was statistically different from the 
observational estimate (p = 1.6 × 10−5). A causal effect of cystatin C was not detected for any 
individual component of CVD.
CONCLUSIONS—Mendelian randomization analyses did not support a causal role of cystatin C 
in the etiology of CVD. As such, therapeutics targeted at lowering circulating cystatin C are 
unlikely to be effective in preventing CVD.
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Cystatin C (encoded by CST3 on 20p11.21) is a potent cysteine protease inhibitor that plays 
pleiotropic roles in human vascular patho-physiology, in particular regulating cathepsins S 
and K (1–3), and serves as a marker of renal function (4). Cathepsins are overexpressed in 
human atherosclerotic and aneurysmal lesions, giving rise to rupture-prone plaques by 
degrading the extracellular matrix (Figure 1) (1). Prospective epidemiological studies show a 
strong association between circulating cystatin C and risk of future coronary heart disease 
(CHD), ischemic stroke (IS), and heart failure (HF) (5,6). This association is also present in 
patients with subclinical atherosclerosis (7) or those at high risk of cardiovascular disease 
(CVD) (8–10), and is independent of renal function determined by formulae on the basis of 
creatinine measurements or other cardiovascular risk factors (5,11–14). Moreover, 
heritability analyses indicate that CVD and cystatin C concentrations have shared polygenic 
backgrounds (15).
The accumulating experimental and epidemiological evidence supports the hypothesis that 
cystatin C could play a causal role in CVD etiology independent of renal function and, as 
such, may be a valid therapeutic target. However, residual confounding and reverse causality 
remain alternative explanations for the strong correlation between cystatin C and CVD, both 
of which are difficult to tease apart from traditional observational studies (16).
Mendelian randomization harnesses the properties of the genome to enable causal inference 
of a biomarker (16). Specifically, the invariant nature of the genome and the random 
distribution of alleles from parents to offspring at conception mean that genetic information 
is not influenced by disease status (reverse causality) and should be free from confounding 
by traditional risk factors. Thus, genetic variation that modulates serum concentrations of 
cystatin C could serve as an instrumental variable to assess the effect of lifelong elevated 
concentrations of cystatin C on disease risk, independent of potential confounders (16).
To this end, we established the Cystatin C Mendelian Randomization Consortium to 
investigate the causal relevance of serum cystatin C to CVD risk. From the published 
genome-wide association studies (GWAS), we identified common single nucleotide 
polymorphisms (SNPs) in the CST3 locus associated with circulating concentrations of 
cystatin C (17–20) and selected rs911119 as showing the strongest association, independent 
from other variants (18). We robustly associated rs911119 with circulating cystatin C in 9 
cohorts (8 of which have not participated in prior GWAS). Next, we evaluated the 
association of serum cystatin C with CVD in observational analyses of prospective cohorts. 
Finally, we used rs911119 as an instrument variable to test the causal effect of circulating 
cystatin C on CVD through Mendelian randomization.
METHODS
We included data from 15 general population–based cohorts and 1 randomized clinical trial 
(Table 1, Online Tables 1 and 2) (detailed study descriptions in Online Appendix). All 
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participants provided informed consent, and the local ethics committees approved these 
studies.
CONSORTIA DATA
We included individual study summary statistics from the discovery stages of 
CARDIoGRAM (Coronary Artery Disease Genome-wide Replication and Meta-analysis), 
including 17 studies, 20,251 CHD cases, and 60,183 control subjects (21) and the 
METASTROKE collaboration (the first large meta-analysis of stroke GWAS data), 
consisting of 15 studies, 12,389 all-cause IS cases, and 62,004 control subjects (22). We also 
included the summary statistics from the C4D (Coronary Artery Disease Genetic 
Consortium) on CHD (23) (including 4 studies comprising 15,388 cases and 15,040 control 
subjects) and CHARGE-HF (Cohorts for Heart and Aging Research in Genomic 
Epidemiology–Heart Failure), the CHARGE GWAS on incident HF, which included 4 
studies, 2,526 cases, and 18,400 control subjects from European descent (24). Additionally, 
we included consortia data on a number of cardiovascular traits (Online Table 3). For the 
primary outcome (CVD), we meta-analyzed genetic association results from the 16 
individual cohorts, CARDIoGRAM, C4D, METASTROKE, and CHARGE-HF. For all 
analyses, we excluded overlapping cohorts where appropriate (Online Table 3).
SNP SELECTION AND GENOTYPING
We searched PubMed and identified 5 publications reporting GWAS conducted for cystatin 
C or its clinical derivative (i.e., estimated glomerular filtration rate [eGFR] on the basis of 
cystatin C) (17–20). From these publications, 3 SNPs were identified (rs1158167 [20], 
rs13038305 [19], and rs911119 [18]), with rs911119 showing the strongest independent 
association with cystatin C. We therefore used rs911119 as our primary SNP of choice. 
When this SNP was not available, we used suitable proxies in linkage disequilibrium with 
rs911119 (r2 ≥0.90) (Online Table 4, Online Figure 1).
The genotyping platforms used by the cohorts are outlined in Online Table 2. All SNPs were 
in Hardy-Weinberg Equilibrium (p > 0.067) (Online Table 5) with a call rate ≥95% or 
imputation quality ≥0.95, and comparable allele frequencies (Online Figure 2). Online 
Tables 6 and 7 describe the SNP characteristics from the individual study data of the 
CARDIoGRAM consortium and METASTROKE collaboration used in our study (21,22). 
The genotyping, imputation and quality control procedures of these and other consortia are 
described in Online Table 3.
Cystatin C (mg/l) was measured in 10 of the 16 prospective cohorts in a total of 37,126 
individuals, of whom 29,805 had genotype data available. The assays used to quantify serum 
cystatin C in each study together with the assay QC parameters are outlined in Online Table 
8. As cystatin C concentrations were not normally distributed, we log2 transformed these 
prior to analysis, enabling us to express associations as “per doubling of cystatin C” in 
observational and Mendelian randomization analyses.
We queried data from the Genotype-Tissue Expression Project (GTEx) through the GTEx 
Portal for rs911119 and its proxies for an effect on CST3 expression in whole blood (25). 
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Details of the study design, tissue collection, sample preparation, ribonucleic acid 
sequencing, genotyping, quality control, and imputation have been described elsewhere (25).
Other expression quantitative trait locus (eQTL) datasets we queried have been described 
before and pertain to expression in monocytes (26), lymphoblastoid cell lines (27), 
fibroblasts, adipocytes, and lymphoblastoid cell lines from the MuTHER (Multiple Tissue 
Human Expression Resource) project (28).
Details on the cardiovascular risk factors and traits that we assessed are given in the Online 
Appendix.
CLINICAL OUTCOMES
Our primary outcome was CVD, a composite of CHD, IS, and HF. We defined CHD as 
morbidity or mortality from myocardial infarction (MI) (International Classification of 
Disease, 10th Revision [ICD-10] codes I21 and I22), acute coronary syndrome, unstable 
angina, >50% coronary artery stenosis on angiography, and/or having an intervention by 
percutaneous coronary angioplasty or coronary artery bypass graft (ICD-10 codes: I20.0, 
I21, and I22; surgical codes: FNG02, FNG05, FNC, FND, and FNE). IS was defined as 
morbidity or mortality originating from occlusion and stenosis of cerebral and pre-cerebral 
arteries; this includes large artery stroke, small vessel disease, and cardioembolic stroke 
(ICD-10: I63). HF was defined as left ventricular failure, (combined) diastolic or systolic 
HF, and unspecified HF, excluding cardiac arrest (ICD-10 code I50).
We further defined secondary outcomes as CHD, IS, HF, and MI. Clinical outcome data 
were obtained from the patient and from cause of death registries or validated events. An 
overview of outcome definitions for each study is provided in Online Table 9.
STATISTICAL ANALYSIS
To standardize the analysis procedure, a pre-specified script was used in every study with 
access to participant data. We conducted observational analysis, genetic analysis, and 
Mendelian randomization analysis. Detailed information is included in the Online Appendix.
Meta-analyses estimates were pooled using a fixed-effects model with between-study 
heterogeneity quantified using the I2 statistic (29). Random effects modeling was used as a 
sensitivity analysis. The total sample size used in each analysis depended on the covariates 
available and the type of case (incident-only or incident plus prevalent) (Online Table 10). 
Effect estimates from logistic and Cox-regression analyses are referred to as relative risks 
(RRs).
We applied Bonferroni correction for multiple testing in the genetic association analyses, 
and we thus set a p value threshold of 0.05/(5 outcomes + 32 cardiovascular traits) = 0.0014. 
When appropriate, we adjusted for the relatedness among samples. For Mendelian 
randomization analyses of clinical events, we estimated the post hoc power as described 
previously (30). We used the genetic sample size and case/control ratios for each outcome 
trait in this study, together with the proportion of variance of cystatin C explained by the 
genetic variant (r2 = 0.0275). We calculated the existing power to detect an effect using a 
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Bonferroni-adjusted 2-sided type 1 error (α) of 0.05/5 = 0.01 (corrected for testing 5 clinical 
outcomes) (Online Figure 3).
Analyses were conducted in Stata Statistical Software Release 13, version 13.1 (StataCorp 
LP, College Station, Texas) and R version 3.2.3 “Wooden Christmas-Tree” (R Foundation 
for Statistical Computing, Vienna, Austria) with R Studio version 0.99.983 (RStudio, Inc., 
Boston, Massachusetts).
RESULTS
The Cystatin C Mendelian Randomization Consortium comprises 15 general population–
based prospective cohorts and 1 randomized clinical trial including up to 76,481 individuals 
from European descent (Table 1, Online Tables 1 and 2). In total, 19,394 cardiovascular 
events were recorded comprising 11,552 CHD events, 7,057 IS cases, 3,009 HF events, and 
8,673 MIs (Table 1). A total of 37,126 individuals had measures of serum cystatin C (Table 
1, Online Table 8). To maximize power (Online Figure 3) for the genetic analyses of risk 
factors and clinical outcomes, we added data from relevant consortia, while excluding 
overlapping data from the 16 participating studies (Online Table 3). The baseline 
characteristics of the consortia were published previously (21–24,31–43).
ASSOCIATION AND SPECIFICITY OF THE GENETIC INSTRUMENT FOR CYSTATIN C 
CONCENTRATIONS
The genetic instrument (rs911119, or its proxies) (Online Table 4, Online Figure 1) had 
similar allele frequencies among the cohorts (Online Figure 2) and showed a strong 
association with circulating cystatin C. In data from 29,805 individuals (who were 
genotyped of the 37,126 in whom cystatin C was measured), each additional copy of the 
minor allele was associated with a 6.13% reduction in cystatin C (95% confidence interval 
[CI]: 5.75 to 6.50; p = 5.95 × 10−211) and explained 2.75% (95% CI: 0.75 to 4.76) of the 
phenotypic variation (F-statistic = 961) (Online Appendix, Online Figure 4). We queried 
various eQTL sources and confirmed that rs911119 only associated with expression of CST3 
and not with that of other genes in the region ±500 kb surrounding rs911119 (Online 
Appendix, Online Figure 5, Online Table 12).
We replicated the association of rs911119 (or its proxies) with cystatin C–based eGFR (0.08 
SD per allele; 95% CI: 0.07 to 0.08; p = 4.00 × 10−124) (Online Figure 6) (17–20). We 
further confirmed a lack of association with creatinine-based eGFR (0.21 SD per allele; 95% 
CI: −0.11 to 0.52; p =0.21) (Online Figure 6) (17–20).
OBSERVATIONAL ASSOCIATIONS OF CIRCULATING CYSTATIN C
In linear regression analyses adjusted for age and sex, higher serum cystatin C 
concentrations were associated with several cardiovascular risk factors and traits (Online 
Figure 7). In contrast, rs911119 showed no significant association with these traits after 
corrections for multiple testing (Online Figure 6). Use of fixed or random effects modeling 
did not alter summary estimates derived from meta-analysis (Online Figure 8).
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An observational meta-analysis adjusted for age and sex showed a strong dose-dependent 
relation between cystatin C concentrations and CVD (Figure 2, Online Figure 9). Per 
doubling of cystatin C concentrations, the risk of CVD increased (RR: 2.33; 95% CI: 2.08 to 
2.62; p = 1.28 × 10−47; 6,220 cases and 25,777 control subjects), with the relationship being 
log-linear (Online Figure 9). Although adjustment for additional confounders diminished the 
association, an independent relation between cystatin C and CVD persisted (RR: 1.82; 95% 
CI: 1.56 to 2.13; p = 2.12 × 10−14) after adjustment for age, sex, high-density lipoprotein 
cholesterol, body mass index, systolic blood pressure, eGFR, and smoking status (Figure 2, 
Online Figure 10, Online Table 11). Adjusting for additional potential confounders (high-
sensitivity C-reactive protein, total cholesterol, and glucose) did not further diminish the 
association (Online Table 11), nor did confining the analysis to incident-only cases (Figure 
2, Online Figure 10). In the fully adjusted observational analysis, cystatin C was also 
associated with an increased risk of CHD, IS, and HF, but not with MI (Figure 3, Online 
Figure 11, Online Table 11).
We meta-analyzed genetic data from 43 studies with 63,292 CVD cases (including 20,251 
CHD cases from CARDIoGRAM, 15,388 CHD cases from C4D, 12,389 IS cases from 
METASTROKE, and 2,526 HF cases from CHARGE) and a total of 188,924 control 
subjects (Online Table 10), but found no association of rs911119 with CVD (RR per minor 
allele: 1.00; 95% CI: 0.98 to 1.02; p = 0.994) (Online Figure 12). Likewise, we found no 
association of the genetic variant with CHD, IS, HF, or MI (Online Figure 12).
MENDELIAN RANDOMIZATION ANALYSIS
In Mendelian randomization analysis, taking into account both the genetic association with 
cystatin C (Online Figure 4) and CVD (Online Figure 12) to triangulate the underlying 
causal effect, we detected no evidence for a causal relation between circulating cystatin C 
and CVD (odds ratio [OR]: 1.00 per doubling of cystatin C; 95% CI: 0.82 to 1.22; p = 
0.994) (Figure 2). This was statistically different from the observational estimate obtained 
from the fully-adjusted model using incident-only events (p for heterogeneity = 1.6 × 10−5). 
Likewise, no causal association of cystatin C was detected for any individual subtype of 
vascular disease (Figure 3).
POWER
With a combined sample size of 63,292 CVD events, 43,068 CHD events, 16,784 IS events, 
and 3,440 HF cases (Online Figure 12), we estimated to have >80% power to detect an OR 
>1.10 per doubling cystatin C for CVD, 1.13 for CHD, 1.19 for IS, and 1.45 for HF (Online 
Figure 3).
DISCUSSION
In this first, large-scale Mendelian randomization analysis, we investigated whether the 
previously reported robust association between circulating cystatin C and risk of CHD and 
ischemic stroke (5,6) was likely to be causal. In our model, adjusted for traditional risk 
factors, cystatin C indeed was strongly associated with CVD risk (Figure 2) in a dose-
dependent manner (Online Figures 9 and 11). Even when limited to incident-only cases and 
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in a fully adjusted analysis, cystatin C had an independent association with clinical events. 
However, in an adequately powered Mendelian randomization approach, we did not identify 
evidence of a causal relationship between circulating cystatin C and CVD or any individual 
cardiovascular component.
Our Mendelian randomization analyses confirmed and extended findings from a recent 
report analyzing data from the population-based Malmö Diet and Cancer study as well as the 
CARDIOGRAM meta-analysis, suggesting a lack of association between an SNP 
(rs13038305, linkage disequilibrium r2 = 0.99 with rs911119) (Online Table 3) in CST3 and 
the risk of CHD (44). However, in that large analysis, a formal instrumental variable 
estimate was not synthesized, nor was the association of the SNP with IS or HF investigated. 
Our meta-analysis, on the basis of data from 43 cohort studies including more than 250,000 
individuals with more than 63,000 cardiovascular events, is by far the largest and most 
comprehensive study to date to examine these associations.
For Mendelian randomization to generate a valid causal estimate, several assumptions 
needed to be fulfilled. One such assumption was sufficient statistical power. We estimated to 
have >80% power to detect ORs smaller than the lower limit of the observed association of 
cystatin C with CVD from multivariate analyses (Online Figure 3).
Another assumption was that the instrument is strongly associated with the biomarker of 
interest. Indeed, common variation in the CST3 locus almost exclusively associated with 
cystatin C (and thus eGFR on the basis of cystatin C) in both previous studies (18) and ours 
(Online Figures 4 and 6). Convincingly, eQTL analyses confirmed that rs911119 was 
strongly associated with CST3 expression, but not with the nearby gene CST9, arguing 
against a potential pleotropic effect (Online Appendix, Online Figure 5). Although we found 
nominally significant associations with diastolic blood pressure, waist circumference, and 
smoking, these associations did not persist after correction for multiple testing.
STUDY LIMITATIONS
In any Mendelian randomization study, the genetic instrument (in this case rs911119) should 
not experience “weak instrument bias” (43). In our study, this seemed very unlikely, given 
the strong association with cystatin C (F-statistic of 961). Furthermore, weak instrument bias 
would bias the causal estimate toward the observational estimate; in contrast, the causal 
estimates that we reported were statistically different from the observed estimates and 
consistently null.
Our study relied on the ability of the assay to quantify serum concentrations of cystatin C 
with sufficient accuracy and precision. Recent studies have shown that genetic variants can 
change the epitope measured by the assay (44,45). We cannot rule out the possibility that our 
instrument (rs911119) or its proxies altered the epitope (versus actually changing the 
quantity of circulating cystatin C), nor can we be certain to what extent such a change would 
affect the ability to detect an association with cystatin C concentrations. Last, in principle, 
the assay type and the time period of measurement could have influenced our findings, 
although in our studies, the mean cystatin C concentrations were comparable (Table 1) and 
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we found consistent associations between our genetic variant and cystatin C (Online Figure 
4) and between cystatin C and risk of CVD across studies.
Although we fitted a multivariate model that extensively adjusted for confounders for 
observational analyses, residual confounding may still exist, which is a classic challenge for 
conventional observational epidemiology. Specifically, as no gold standard measurements of 
renal function (such as inulin-based GFR measurements) were quantified in studies 
contributing to this analysis, it remains possible that residual confounding by impaired 
kidney function remained and was not fully accounted for by adjustments in our 
observational analyses. As a biomarker for kidney function, cystatin C has proven its value 
and represents a stronger predictor for CVD risk than does creatinine (4). Thus, although our 
analyses provided no evidence for a causal association between cystatin C and CVD, it did 
not preclude the use of cystatin C in disease prediction.
We should note that considerable heterogeneity (I2) existed in our observational analysis 
(Online Figure 7). This might have been due to the number of studies included (up to 8) in 
our observational analysis (as compared with the genetic analysis). Conversely, little 
heterogeneity existed in our genetic analysis (Online Figure 6). Adding more studies to the 
observational analysis (46) or stratifying on the basis of these subgroups (29) might reduce 
heterogeneity and/or identify potential characteristics that account for heterogeneity. Also, a 
more uniform definition of clinical outcomes across studies contributing toward the 
observational analysis of cystatin C and event risk might reduce the heterogeneity further.
CONCLUSIONS
We conducted a comprehensive Mendelian randomization of circulating cystatin C in the 
development of CVD in the general population. Our findings suggest that residual 
confounding (e.g., by impaired renal function) and/or reverse causality, rather than a causal 
effect of cystatin C per se, likely explained the observational relationship between cystatin C 
and clinical events (Central Illustration). As such, interventions aimed at lowering 
circulating cystatin C are unlikely to represent an effective means to prevent CVD.
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CHD coronary heart disease
CST3 gene encoding for the protein cystatin C
CVD cardiovascular disease
HF heart failure
IS ischemic stroke
MI myocardial infarction
SNP single nucleotide polymorphism
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APPENDIX
For an expanded Methods section and supplemental figures and tables, please see the online 
version of this article.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE
Epidemiological studies show a strong association between circulating cystatin C 
concentrations and cardiovascular risk, independent of renal function, but the results of a 
large Mendelian randomization study do not support a causal relationship.
TRANSLATIONAL OUTLOOK
Investigators should consider whether the available data are sufficient to forego 
prospective studies of measures that lower circulating cystatin C to prevent CVD.
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FIGURE 1. Presumed Mechanism of Cystatin C in Plaques
In vivo and in vitro animal and human studies have shown elevated levels of cathepsins and 
lower levels of cystatin C—a potent cathepsin inhibitor—in atherosclerotic tissue. 
Cathepsins are thought to degrade the extracellular matrix (ECM), thus facilitating the 
migration of smooth muscle cells (SMCs) to the plaque core and promoting the 
destabilization.
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FIGURE 2. Estimates of the Association of Circulating Cystatin C With CVD Risk
The observational models were minimally adjusted for age and sex (minimal), or fully 
adjusted for age, sex, body mass index, smoking, high-density lipoprotein cholesterol, 
estimated glomerular filtration rate, and systolic blood pressure (full). The causal estimates 
were triangulated using effect estimates of the association of the genetic instrument with 
cystatin C concentrations (reported in Online Figure 4) and cardiovascular disease (CVD) 
(Online Figure 12). Total sample sizes may differ from those reported in Table 1 due to the 
availability of covariates. adj. = adjusted; CI = confidence interval; RR = relative risk.
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FIGURE 3. Estimates of the Association of Circulating Cystatin C on Other Cardiovascular 
Outcomes
The observational models were minimally or fully adjusted and causal model estimates were 
triangulated as described in Figure 2. Total sample sizes may differ from those reported in 
Table 1 due to the availability of covariates. Abbreviations as in Figure 2.
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FIGURE 4. CENTRAL ILLUSTRATION Assessing Causality of Cystatin C in CVD
(A) Epidemiological evidence shows that increased levels of circulating cystatin C are 
associated with increased risk of disease. Whether this relation is truly causal or is a 
consequence of confounding or reverse causality is hard to determine. Our study replicated 
the strong observational associations between circulating concentrations of cystatin C and 
risk of cardiovascular diseases (CVDs), but also showed that cystatin C was associated with 
many potential confounders. (B) We used a genetic variant (rs911119) in the gene CST3, 
which associates with CST3 gene expression and directly encodes cystatin C. The genetic 
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variant showed a very strong association with circulating cystatin C concentrations, but not 
with potential confounders. In Mendelian randomization analysis, no evidence for a causal 
association with CVD was identified. Thus, our study provides no evidence in support of a 
causal role for circulating cystatin C in the etiology of atherosclerotic vascular disease. HDL 
= high-density lipoprotein; LDL = low-density lipoprotein; SNP = single nucleotide 
polymorphism.
van der Laan et al. Page 20
J Am Coll Cardiol. Author manuscript; available in PMC 2017 August 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
van der Laan et al. Page 21
TA
B
LE
 1
Ch
ar
ac
te
ris
tic
s o
f P
ro
sp
ec
tiv
e 
Co
ho
rts
St
ud
y
To
ta
l
SN
P*
C
ys
ta
tin
 C
†
C
V
D
‡
C
H
D
‡
IS
‡
H
F‡
M
I‡
M
al
e
A
ge
 (y
rs)
C
ys
ta
tin
 C
 (m
g/d
l)
3C
6,
44
0
6,
43
5
1,
24
4
1,
71
7
1,
23
5
45
9
43
9
48
6
39
.1
9
74
.3
0 
± 
5.
52
0.
92
 ±
 0
.2
4
EP
IC
-N
L
6,
26
5
5,
19
2
—
1,
96
7
1,
43
0
53
7
—
1,
43
0
22
.3
9
53
.8
0 
± 
10
.2
3
—
G
O
SH
1,
47
8
1,
47
9
—
49
3
11
1
23
5
23
3
—
42
.0
8
51
.0
8 
± 
11
.8
6
—
H
R
S
7,
84
4
5,
58
5
5,
77
7
—
—
—
—
—
—
—
0.
64
 ±
 0
.3
4
K
O
RA
4,
85
6
1,
86
7
4,
67
6
54
0
34
1
25
5
—
34
1
49
.5
3
49
.7
5 
± 
14
.1
1
0.
80
 ±
 0
.2
1
N
BS
1,
81
9
1,
29
7
—
66
—
66
—
17
0
49
.4
8
61
.0
5 
± 
10
.2
6
—
PI
V
U
S
1,
01
6
94
9
1,
00
4
25
5
17
5
71
75
10
5
49
.9
0
70
.2
0 
± 
0.
17
0.
90
 ±
 0
.1
9
PR
EV
EN
D
3,
24
5
3,
24
5
3,
24
5
23
6
19
0
58
—
—
50
.2
6
49
.4
2 
± 
12
.2
5
0.
87
 ±
 0
.1
7
PR
O
SP
ER
§
5,
24
4
5,
15
0
—
2,
56
1
2,
03
4
77
9
21
1
76
2
48
.1
3
75
.3
4 
± 
3.
35
—
R
ot
te
rd
am
7,
98
3
5,
97
4
3,
90
6
3,
57
9
1,
93
4
1,
32
8
1,
62
5
1,
17
6
38
.9
0
73
.0
6 
± 
7.
49
1.
11
 ±
 0
.2
8
SH
IP
3,
22
4
3,
22
4
3,
21
2
11
4
19
87
—
13
4
48
.0
8
54
.4
6 
± 
15
.2
6
0.
88
 ±
 0
.3
0
Tr
o
m
sø
6,
12
9
—
6,
12
9
1,
25
1
—
49
4
—
88
1
47
.5
9
60
.5
9 
± 
10
.2
5
0.
86
 ±
 0
.1
8
TW
IN
G
EN
E||
6,
90
2
6,
90
2
6,
74
0
93
2
61
0
28
7
20
6
—
47
.2
3
64
.8
3 
± 
8.
26
1.
02
 ±
 0
.3
0
U
LS
A
M
1,
22
1
1,
10
7
1,
19
3
50
3
28
5
17
5
22
0
—
10
0.
00
71
.0
0 
± 
0.
64
1.
25
 ±
 0
.2
7
W
H
I
7,
85
4
7,
84
4
—
4,
83
1
2,
93
4
2,
11
5
—
2,
93
4
0.
00
67
.9
7 
± 
6.
58
—
W
hi
te
ha
ll 
II
4,
96
1
5,
01
1
—
34
9
25
4
11
1
—
25
4
74
.5
8
49
.1
9 
± 
5.
99
—
O
ve
ra
ll
76
,4
81
61
,2
61
37
,1
26
19
,3
94
11
,5
52
7,
05
7
3,
00
9
8,
67
3
—
—
—
Va
lu
es
 a
re
 n
, %
, o
r m
ea
n 
± 
SD
.
*
To
ta
l n
um
be
r o
f i
nd
iv
id
ua
ls 
w
ith
 g
en
ot
yp
e 
da
ta
.
† G
en
et
ic
 d
at
a 
w
er
e 
av
ai
la
bl
e 
in
 2
9,
80
5 
of
 th
e 3
7,
12
6 
in
di
v
id
ua
ls 
th
at
 h
ad
 v
al
ue
s f
or
 cy
sta
tin
 C
, w
hi
ch
 w
e 
us
ed
 to
 a
ss
oc
ia
te
 rs
91
11
19
 w
ith
 ci
rc
ul
at
in
g 
cy
sta
tin
 C
. F
o
r 
th
e 
ge
ne
tic
 a
na
ly
sis
 o
f C
V
D
, C
H
D
, I
S,
 
an
d 
H
F,
 
co
ho
rts
 th
at
 c
on
tri
bu
te
d 
to
w
ar
d 
co
ns
or
tia
 w
er
e 
ex
cl
ud
ed
.
‡ In
di
ca
te
s t
ot
al
 in
ci
de
nt
 a
nd
 p
re
v
al
en
t c
as
es
 o
f d
ise
as
e 
or
 c
om
po
sit
e 
di
se
as
es
 in
 th
e 
ca
se
 o
f C
V
D
.
§ P
RO
SP
ER
 is
 a
 ra
nd
om
iz
ed
 c
lin
ic
al
 tr
ia
l.
|| Fo
r 
th
e 
as
so
ci
at
io
n 
of
 S
N
P 
w
ith
 cy
sta
tin
 C
 c
on
ce
nt
ra
tio
ns
, 9
,4
88
 sa
m
pl
es
 w
er
e a
v
ai
la
bl
e 
in
 T
W
IN
G
EN
E.
CH
D
 =
 c
or
on
ar
y 
he
ar
t d
ise
as
e;
 C
V
D
 =
 c
ar
di
ov
as
cu
la
r d
ise
as
e;
 H
F 
= 
he
ar
t f
ai
lu
re
; I
S 
= 
isc
he
m
ic
 st
ro
ke
; M
I =
 m
yo
ca
rd
ia
l i
nf
ar
ct
io
n;
 S
N
P 
= 
sin
gl
e-
nu
cl
eo
tid
e 
po
ly
m
or
ph
ism
.
J Am Coll Cardiol. Author manuscript; available in PMC 2017 August 30.
